Multiple Myeloma Medications

*generic version available

E experimental

Chemotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Chemotherapy	Multiple	Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.
Farydak	panobinostat	Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).
Xpovio	selinexor	Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

Immunotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Pomalyst	pomalidomide	Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.
Revlimid	lenalidomide	Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab), and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.
Thalomid	thalidomide	Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

Targeted Therapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Blenrep	belantamab mafodotin	Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.
Darzalex, Darzalex Faspro	daratumumab	Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.
Empliciti	elotuzumab	Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Kyprolis	carfilzomib	Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.
Ninlaro	ixazomib	Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Sarclisa	isatuximab-irfc	Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.
Velcade	bortezomib	Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

DRUG Chemotherapy

GENERIC NAME Multiple

DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Farydak

GENERIC NAME panobinostat

DRUG INDICATION

Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

DRUG Xpovio

GENERIC NAME selinexor

DRUG Xpovio

DRUG INDICATION
Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

DRUG Pomalyst

GENERIC NAME pomalidomide

DRUG INDICATION
Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.

DRUG Revlimid

GENERIC NAME lenalidomide

DRUG INDICATION
Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab),
and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Thalomid

GENERIC NAME thalidomide

DRUG INDICATION
Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

DRUG Blenrep

GENERIC NAME belantamab mafodotin

DRUG INDICATION
Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

DRUG Darzalex, Darzalex Faspro

GENERIC NAME daratumumab

DRUG INDICATION
Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.

DRUG Empliciti

GENERIC NAME elotuzumab

DRUG INDICATION
Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Kyprolis

GENERIC NAME carfilzomib

DRUG Kyprolis

DRUG INDICATION
Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

DRUG Ninlaro

GENERIC NAME ixazomib

DRUG INDICATION
Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Sarclisa

GENERIC NAME isatuximab-irfc

DRUG INDICATION
Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.

DRUG Velcade

GENERIC NAME bortezomib

DRUG INDICATION
Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

© 2026 Smart + Strong All Rights Reserved.